New Technology– category –
-
SelectBIO to Host Lipid Nanoparticles (LNPs) Asia/Pacific 2026: Driving mRNA Delivery Innovations
SelectBIO Conferences UK Overview SelectBIO Conferences will host the 'Lipid Nanoparticles (LNPs) Asia/Pacific 2026' event, focusing on LNPs, extracellular vesicles, exosomes, and Japanese research. The conference will primarily address ... -
iPSC-Derived Cell Therapy Pipeline 2026: From Disease Modeling to Expanding Clinical Applications
BioInformant USA Overview As of 2026, the iPSC-derived cell therapy pipeline shows rapid advancements in disease modeling and drug discovery, though broad clinical use in human patients still faces challenges. iPSC-derived cells hold imm... -
iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies
RegMedNet UK Overview iRegene Therapeutics announced its allogeneic iPSC-derived therapy, NouvNeu001, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for Parkinson's disease, following its prior Fast ... -
CRISPR Therapeutics Honored with 2026 Global Recognition Award for Pioneering Gene-Editing Advances
Global Recognition Awards USA Overview CRISPR Therapeutics received the 2026 Global Recognition Award for its significant advancements in gene editing and personalized medicine. Leveraging CRISPR-Cas9 technology, the company has develope... -
NIH-Funded Breakthrough Miniaturizes CRISPR for Precision In Vivo Gene Delivery
National Institutes of Health (NIH) USA Overview An NIH-funded team has discovered and enhanced a remarkably compact CRISPR gene-editing system, Al3Cas12f, enabling precision in vivo delivery. This natural enzyme, small enough to fit wit... -
Advanced Lipid Nanoparticles Revolutionize Nucleic Acid and Gene-Editing Therapeutic Delivery
PMC (PubMed Central) USA Overview Lipid nanoparticles (LNPs) are becoming indispensable for efficient intracellular delivery of nucleic acid, mRNA, and gene-editing therapeutics, shielding them from degradation in circulation. Proven eff... -
Pioneering Pluripotency: Japan Approves World’s First iPSC-Derived Therapies for Heart Failure and Parkinson’s
再生医療 みなとみらい麻の葉クリニック Japan Overview In a historic global first, Japan's Ministry of Health, Labour and Welfare has granted conditional and time-limited approval to two induced pluripotent stem cell (iPSC)-derived regener... -
iPSC Clinical Trials Deliver Breakthroughs: Parkinson’s, Heart Failure, Cancer Immunotherapies Show Promising Results
Americord Registry USA Overview Induced pluripotent stem cell (iPSC) research is rapidly transforming medicine, with multiple clinical trials reporting significant progress across diverse disease areas. A Kyoto University Hospital trial ... -
FUJIFILM Cellular Dynamics Quadruples iPSC Manufacturing Capacity with New Madison Facility
FUJIFILM Cellular Dynamics USA Overview FUJIFILM Cellular Dynamics (FCDI) has inaugurated a new headquarters and iPSC development and manufacturing facility in Madison, Wisconsin. This strategic expansion quadruples FCDI's capacity for p... -
Laser-Precision 3D Bioprinting: Ushering in a New Era for Organoid and Tissue Engineering
技術情報発信（素材技術を未来へ） Japan Overview Advances in 3D bioprinting are enabling the creation of highly complex organoid and tissue models, transcending the limitations of random self-assembly. Key innovations, such as Poietis' NG...
